ClinTech Research

ClinTech Research is a service company focused on preclinical drug development. It is an integrating Contract Research Organization (CRO) that works through a global network of CRO collaborators that specializes in biological and chemistry studies required for filing an Investigational New Drug (IND).

Our clients are mainly biotechnology companies and academic groups that do not have in house drug development capabilities. The company is the client's preclinical drug development partner, and can manage the whole process including the filing of the IND.

Preclinical development outsourcing services that includes Toxicology & Pharmacology services through a network of pre-qualified Preclinical CROs in India and in the USA. We offer both non-GLP and GLP.


more info

Our vendor-independent preclinical study monitoring services in India to ensure that preclinical study meets the requirements for US FDA, ICH, OECD GLP guidelines.


more info

We leverage our US-India experience to facilitate your R&D venture into both countries. As your local partner, we can be your guide to the business operations in India or USA.


more info

ClinTech Research has a number of differentiating characteristics namely:

Provides access to a broad global choice of CRO collaborators and consultants that can be matched to clients special needs.

Technical professionals with extensive experience in drug development project management in the pharmaceutical industry.

Management of the interfaces between various biological and chemistry disciplines involved in preclinical drug development.

An in depth knowledge of drug development as a result of working on a wide variety of projects for many different companies.

We are looking for that biotechnology, pharmaceutical, nutraceutical and other life sciences company which are interested in outsourcing their preclinical development from preliminary assessment of a drug's safety and efficacy to GLP-compliant Safety Pharmacology and Regulatory Toxicology studies for First-In-Human IND submission, and subsequently, an NDA or BLA.